The GlaxoSmithKline diabetes drug Avandia is being reviewed by the Food and Drug Administration (FDA). Recent analysis has found the drug may not be as risky as once thought. Fear of heart attack linked to the drug impost strict regulations in 2010, but the FDA may lift said restrictions following a vote this week. As a result, restrictions regarding which patients can get a prescription for Avandia may be lifted. Read the full story.